BR112015016433A2 - compostos, composição farmacêutica, uso de um composto, método de tratamento de um distúrbio e combinação - Google Patents

compostos, composição farmacêutica, uso de um composto, método de tratamento de um distúrbio e combinação

Info

Publication number
BR112015016433A2
BR112015016433A2 BR112015016433A BR112015016433A BR112015016433A2 BR 112015016433 A2 BR112015016433 A2 BR 112015016433A2 BR 112015016433 A BR112015016433 A BR 112015016433A BR 112015016433 A BR112015016433 A BR 112015016433A BR 112015016433 A2 BR112015016433 A2 BR 112015016433A2
Authority
BR
Brazil
Prior art keywords
alkyl
treating
compound
disorder
compounds
Prior art date
Application number
BR112015016433A
Other languages
English (en)
Other versions
BR112015016433B1 (pt
Inventor
Bertolotti Anne
Guedat Philippe
Original Assignee
Inflectis Bioscience
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflectis Bioscience, Medical Res Council filed Critical Inflectis Bioscience
Publication of BR112015016433A2 publication Critical patent/BR112015016433A2/pt
Publication of BR112015016433B1 publication Critical patent/BR112015016433B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

resumo “compostos, composição farmacêutica, uso de um composto, método de tratamento de um distúrbio e combinação” a presente invenção se refere a um composto de fórmula (i), ou umtautômero e/ou um sal farmaceuticamente aceitável do mesmo, em que: r1 é a alquila, cl, f ou br; r2 é o h ou f; r3 é selecionado a partir de h e alquila; r4 é selecionado a partir de h e c(o)r6; r5 é o h; ou r4 e r5 estão ligados para formar um grupo heterocíclico, que opcionalmente é substituído com um ou mais grupos r10; r6 é selecionado a partir de r7, or7 e nr8r9; r7, r8 e r9 são cada um independentemente selecionados a partir de alquila, cicloalquila, aralquila, cicloalquenila, heterociclila e arila, cada uma opcionalmente é substituída com um ou mais grupos r10; cada r10 é independentemente selecionado a partir de halogênio, oh, cn, no2, coo-alquila, aralquila, so2-alquila, so2-arila, cooh, co-alquila, co-arila, nh2, nh-alquila, n(alquil)2, cf3, alquila e alcóxi; x e z são cada um, independentemente, o cr11, e y é selecionado a partir de cr11 e n; e r11 é o h ou f; para a utilização no tratamento de um distúrbio associado com a tensão do dobramento incorreto da proteína e, em especial, associado com o acúmulo de proteínas dobradas erradas.
BR112015016433-1A 2013-01-10 2014-01-10 Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína BR112015016433B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
GB1300435.3 2013-01-10
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (2)

Publication Number Publication Date
BR112015016433A2 true BR112015016433A2 (pt) 2017-07-11
BR112015016433B1 BR112015016433B1 (pt) 2023-06-27

Family

ID=

Also Published As

Publication number Publication date
HUE030848T2 (hu) 2017-06-28
US10526297B2 (en) 2020-01-07
CN105189452B (zh) 2018-12-18
US9682943B2 (en) 2017-06-20
RU2654910C2 (ru) 2018-05-25
KR102166665B1 (ko) 2020-10-16
US10100020B2 (en) 2018-10-16
RU2015127827A (ru) 2017-01-12
US20200095210A1 (en) 2020-03-26
ES2831453T3 (es) 2021-06-08
MX370491B (es) 2019-12-16
CA2896976A1 (en) 2014-07-17
IL239629A0 (en) 2015-08-31
PT2943467T (pt) 2016-10-18
JP6276289B2 (ja) 2018-02-07
EP3115357B1 (en) 2020-08-12
EP2943467A1 (en) 2015-11-18
IL239629B (en) 2018-03-29
KR20150127574A (ko) 2015-11-17
US20160046589A1 (en) 2016-02-18
MX2015008977A (es) 2016-05-16
PL2943467T3 (pl) 2017-01-31
AU2014204831B2 (en) 2017-09-07
RS55185B1 (sr) 2017-01-31
US20170247344A1 (en) 2017-08-31
AU2017272151A1 (en) 2017-12-21
AU2017272151B2 (en) 2018-11-08
CN105189452A (zh) 2015-12-23
GB201300435D0 (en) 2013-02-27
ES2594378T3 (es) 2016-12-19
SI2943467T1 (sl) 2016-11-30
JP2016504400A (ja) 2016-02-12
EP2943467B1 (en) 2016-07-13
US10954198B2 (en) 2021-03-23
CA2896976C (en) 2021-03-02
HRP20161208T1 (hr) 2016-11-04
DK2943467T3 (en) 2016-10-03
US20180354914A1 (en) 2018-12-13
LT2943467T (lt) 2016-10-10
EP3115357A1 (en) 2017-01-11
WO2014108520A1 (en) 2014-07-17
AU2014204831A1 (en) 2015-07-23
AU2014204831C1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX370491B (es) Derivados de bencilidenguanidina y uso terapeutico para tratamiento de enfermedades causadas por proteinas mal plegadas.
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
EA201591703A1 (ru) Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина
BR112016022785B8 (pt) composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3-dioxigenase (ido), composição farmacêutica, e, uso de composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3dioxigenase (ido) ou de um sal farmaceuticamente aceitável do mesmo para fabricação de um medicamento
BR112015013450A8 (pt) compostos bicíclicos, uso dos compostos, composição farmacêutica, complexo molecular e processo para preparação dos referidos compostos
AR095347A1 (es) Compuestos orgánicos
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
AR089768A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
BR112017000943A2 (pt) ácidos carboxílicos heterocíclicos como ativadores de guanilato ciclase solúveis
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015016585A2 (pt) Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
BR112015004529A2 (pt) alcóxi pirazóis como ativadores de guanilato ciclase solúvel
TR201904327T4 (tr) Dimetilbenzoik asit bileşikleri.
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.
EA201491820A1 (ru) Новые тиенопиримидиновые производные, способы их получения и их терапевтические применения
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112012031340A2 (pt) derivados de cianoquinolina
BR112015026967A2 (pt) compostos fenoxietil di-hidro-1h-isoquinolina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: INFLECTIS BIOSCIENCE (FR) ; UNITED KINGDOM RESEARC

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/01/2014, OBSERVADAS AS CONDICOES LEGAIS